Results 191 to 200 of about 43,170 (263)
ABSTRACT Background Alzheimer's disease (AD), a neurodegenerative disorder, is pathologically defined by the accumulation of amyloid‐β (Aβ) plaques, hyperphosphorylated tau tangles and sustained neuroinflammation. Glucagon‐like peptide‐1 (GLP‐1), originally characterised as an incretin hormone, is also expressed endogenously in the brain.
Jianping Li +12 more
wiley +1 more source
Increased dipeptidyl peptidase 4 in patients with concomitant transthyretin cardiac amyloidosis and severe aortic stenosis. [PDF]
Holt MF +11 more
europepmc +1 more source
ABSTRACT Type 2 diabetes mellitus (T2DM) has increasingly been identified as a risk factor for sensorineural hearing loss, whereas the association between different antidiabetic therapies and hearing thresholds remains poorly characterized. This retrospective observational study evaluated 240 patients with T2DM and 105 normoglycemic controls who ...
Francesco Martines +8 more
wiley +1 more source
Caution in handling switchers in pharmacoepidemiologic studies estimating treatment effects: the example of dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease. [PDF]
Wang T +15 more
europepmc +1 more source
ABSTRACT Incretin effect helps in regulating glucose homeostasis and maintaining glycaemic control within the human body. This effect is achieved by the two naturally occurring incretin hormones: glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1).
Nora H. J. Alharbi
wiley +1 more source
Increased Dipeptidyl Peptidase-4 Promotes Adipose Inflammation and Dysfunction in Mice Under Chronic Stress. [PDF]
Zhang M +10 more
europepmc +1 more source
Bullous Pemphigoid Secondary to Dipeptidyl Peptidase-4 (DPP4) Inhibitor: A Case Report. [PDF]
Rosa R +4 more
europepmc +1 more source
This large‐scale real‐world Chinese study demonstrates glycemic clinical control rates (HbA1c > 7%) at baseline and 6 months across key subgroups, including age, baseline HbA1c, body mass index, and treatment regimen. In this prospective real‐world study of fixed‐dose combination metformin and empagliflozin in Chinese patients with type 2 diabetes ...
Weijian Ke +51 more
wiley +1 more source

